

To: CHMP

European Medicines Agency Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands

Suresnes, 27 March 2023

Subject: Withdrawal of the Marketing Authorisation Application for: Tidhesco 250 mg Film-coated Tablets (Ivosidenib, INN) EMEA/H/C/006174

Dear Sirs,

We, Les Laboratoires Servier, have taken the decision to request the withdrawal of the European Marketing Authorisation Application **Tidhesco 250 mg Film-coated Tablets** (**Ivosidenib, INN**) – **EMEA/H/C/006174** – which was a duplicate of the European Marketing Authorisation Application Tibsovo 250 mg Film-coated Tablets (Ivosidenib, INN) – EMEA/H/C/005936.

We would like to take this opportunity to thank the CHMP Rapporteurs and members, and the EMA for the time and efforts dedicated to their review of this application, and the guidance provided during the procedure.

Should you need any further information, please do not hesitate to contact us.

Yours sincerely,